BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a naturally occurring protein found in human gastric juice called Body Protection Compound. Unlike most peptides, BPC-157 is remarkably stable in gastric acid, which is why researchers have explored both injectable and oral administration routes.
The peptide's primary mechanism involves upregulation of growth hormone receptors and activation of the FAK-paxillin signaling pathway, which promotes fibroblast migration and collagen deposition at injury sites. It also stimulates angiogenesis — the formation of new blood vessels — through VEGFR2 pathway activation, improving blood flow to damaged tissues.
In the nitric oxide (NO) system, BPC-157 appears to modulate NO synthase activity, which plays a role in inflammation regulation, blood vessel dilation, and tissue repair signaling. This multi-pathway approach is what makes BPC-157 one of the most broadly studied peptides in regenerative research.
BPC-157 has one of the most extensive preclinical research profiles of any peptide in the regenerative space. While human clinical trials remain limited, the volume of animal and in vitro data is substantial.
Tendon & Muscle Healing: In rat models with transected Achilles tendons, BPC-157 treatment increased biomechanical tendon strength and accelerated fibroblast outgrowth from tendon explants. Separate studies on quadriceps muscle injuries showed a 92% increase in biomechanical muscle strength after 72 hours compared to controls.
Gut Protection: In rats with colon-to-colon anastomosis, BPC-157 improved healing of colon defects, increasing bursting pressure by approximately 62% and biomechanical resistance by roughly 77% versus controls. Multiple studies have also demonstrated protective effects against NSAID-induced gastric lesions.
Neurologic models: Research in spinal cord injury models showed BPC-157 treatment led to recovery of tail function, resolved spasticity, and counteracted axonal necrosis and demyelination. In traumatic brain injury models, the peptide reduced oxidative stress and neuronal loss in the hippocampus.
Bone Healing: Studies have demonstrated accelerated bone fracture healing with improved callus formation and bone mineral density at fracture sites.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
No validated human regimen: BPC-157 has no FDA-approved human dosing schedule, route, cycle length, or stacking protocol. Animal-study doses and informal community protocols should not be converted into self-treatment instructions.
Combination research: BPC-157 is often discussed with TB-500, GHK-Cu, or KPV, but controlled human trials have not established the safety or benefit of these combinations.
Human safety evidence is too limited to establish a reliable adverse-event profile. A 2025 two-person IV pilot reported no adverse effects during the short observation period, but that sample is far too small to establish safety.
FDA reviewers have highlighted uncertainty around immunogenicity, peptide-related impurities, API characterization, route-specific risk, and the lack of adequate human safety data.
Research product sources and suppliers. Review each product page and documentation before ordering. US-only restrictions may apply; use code POWER where applicable.
BPC-157 is not an FDA-approved drug. FDA removed it from Category 2 after the underlying nominations were withdrawn, and in July 2026 an FDA advisory committee recommended adding BPC-157 free base and acetate to the 503A Bulks List. That recommendation is non-binding and does not itself authorize compounding or establish drug approval.
Both oral and parenteral routes appear in research, but adequate human comparative trials have not established a clinically superior route for GI, musculoskeletal, or systemic conditions. There is no validated human route, dose, or injection-site protocol.
There is no reliable human evidence establishing a BPC-157 treatment timeline for tendon, ligament, GI, or other conditions. Anecdotal timelines should not be presented as expected results.
BPC-157 is discussed online alongside TB-500, GHK-Cu, and KPV, but controlled human trials have not established the safety, effectiveness, compatibility, or dosing of these combinations.
No validated human BPC-157 cycle length or evidence-based cycling schedule has been established. Community or clinic protocols should not be treated as proven best practice.
Take our 2-minute quiz to explore educational peptide topics based on your research interests. It does not provide a treatment recommendation.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. This page does not provide a BPC-157 treatment protocol, dose, cycle, route, or expected-results timeline. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.